Articles Alert

Department of Microbiology & Immunology University of Illinois Chicago The gene defective in cystic fibrosis patients was identified and sequenced last year. Now that the quite different research skills of physiology and molecular genetics groups have been put together, the wild-type normal gene has been transfected into cultured defective cells and shown to work. There still is a long, long way to go before the disease can be cured by gene therapy. Already the cloned gene will be useful in d

Written bySimon Silver
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Department of Microbiology & Immunology
University of Illinois Chicago

The gene defective in cystic fibrosis patients was identified and sequenced last year. Now that the quite different research skills of physiology and molecular genetics groups have been put together, the wild-type normal gene has been transfected into cultured defective cells and shown to work. There still is a long, long way to go before the disease can be cured by gene therapy. Already the cloned gene will be useful in diagnosis and in developing drug therapy. Developing methods for actual gene replacement in dysfunctional cells in humans will be much more difficult.

M.L. Drumm, H.A. Pope, W.H. Cliff, J.M. Rommens, et al., "Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer," Cell, 62, 1227-33, 21 September 1990. (University of Michigan, Ann Arbor; University of Alabama, Birmingham; Hospital For Sick Children, Toronto)

D.P. Rich, M.P. Anderson, R.J. Gregory, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies